Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
52W High
$23.76
52W Low
$5.90
MA Status:
50D: Below
200D: Above
Beta (~1 neutral, <0.9 lower risk)
2.28
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-5.51
EV/Revenue (<3 favorable)
17.74
P/S (TTM) (<3 favorable)
24.49
P/B (<3 favorable)
1.81
Ownership
Institution‑heavySource: Overview
Insiders (1–5% typical)
4.89%
Institutions (25–75% balanced)
88.36%
Shares Outstanding
107,347,000
Float
101,923,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
52,857,000
Gross Profit (TTM)
-387,246,016
EPS (TTM)
-4.69
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-7.72%
ROE (TTM) (>15% strong)
-0.57%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
1.05
Momentum
Bearish momentumValue
0.1625
Previous
0.0928
Trend
Rising
Signal Cross
No cross
As of
Sep. 05, 2025